Rafael Holdings, Inc. Class B (RFL)

Over the past six months, Rafael Holdings' stock price has declined by approximately 29.06%. Key events impacting the stock price include the merger with Cyclo Therapeutics in March 2025, which shifted the company's focus to Trappsol® Cyclo™. A $25 million rights offering in June 2025 bolstered the company's balance sheet, with strong insider commitment. The Phase 3 TransportNPC™ study of Trappsol® Cyclo™ continued after a Data Monitoring Committee review in June 2025. Preliminary data from a Phase 3 sub-study of Trappsol® Cyclo™ in young patients was presented in September 2025. The company reported a full-year net loss of $30.5 million in October 2025, reflecting increased R&D spending. A net loss of $9.8 million was reported for the first quarter of fiscal 2026 in December 2025, with rising research and development expenses. Insider sentiment has been positive, with high-impact open-market purchases from insiders, including CEO Howard S. Jonas, in June 2025.

Demand seasonality for Rafael Holdings, Inc.'s products and services is not significantly impacted by traditional seasonal patterns. Demand for Trappsol® Cyclo™ is driven by medical need and the progression of clinical trials and regulatory approvals. Revenue from the real estate and infusion technology segments has been reported as stable or increasing, indicating no strong seasonal demand. The company's primary value driver, its pharmaceutical pipeline, is subject to the timelines and outcomes of clinical trials and regulatory processes, which do not typically exhibit seasonality.

Rafael Holdings, Inc. (RFL) is a publicly traded company focused on healthcare and real estate, with a shift towards clinical-stage biotechnology. The company operates through three segments: Healthcare, Infusion Technology, and Real Estate. The Healthcare segment focuses on clinical and early-stage pharmaceutical companies and medical devices, with Trappsol® Cyclo™ as its lead drug candidate in Phase 3 trials for Niemann-Pick Disease Type C1 (NPC1). The Infusion Technology segment manages equity interests in companies like Day Three Labs, which develops surgical and procedural devices. The Real Estate segment maintains a portfolio of commercial and residential properties, including a commercial building in Israel and the company's headquarters in Newark, New Jersey.

Rafael Holdings, Inc. has operations and interests primarily in the United States and Israel. Its main real estate asset, 520 Broad Street, is located in Newark, New Jersey, and it also holds a commercial property in Jerusalem, Israel.

Rafael Holdings' brand reputation is largely tied to the progress and potential of Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (NPC1). The company's focus on a rare and fatal genetic disease garners strong patient advocacy and public support. The company may face scrutiny regarding its pricing strategy if Trappsol® Cyclo™ is approved, even with Orphan Drug status. The company's financial performance, including reported net losses due to high R&D expenses, also influences its reputation among investors.

Ownership of Rafael Holdings, Inc. is concentrated among insiders. Howard S. Jonas, the Executive Chairman and CEO, is the largest individual shareholder, owning approximately 36.81% of all shares and holding 50.4% of the aggregate voting power. Other significant insider owners include I9 Plus LLC, William Conkling, N. Scott Fine, Patrick Fabbio, and David Polinsky. As of February 3, 2026, Rafael Holdings has 78 institutional owners and shareholders holding a total of 4,312,345 shares. Major institutional shareholders include Vanguard Group Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Ieq Capital, Llc, Geode Capital Management, Llc, BlackRock, Inc., and Dimensional Fund Advisors Lp. Institutions hold approximately 8.18% of the shares outstanding.